CD46 and lymphoma: For example, instead of engaging the oncolytic properties of AdV vectors, Wang et al. developed a recombinant AdV35 fiber knob protein, Ad35K++, that can transiently remove CD46 from the cell surface for the purpose of sensitizing lymphoma cells to CDC killing triggered by the CD20-specific mAb, rituximab (116).